

Published on *Global Research Projects* (<https://globalprojects.ucsf.edu>)

Home > A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence

---

# **A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence**

© 2019 The Regents of the University of California

**Brought to you by:**



**Created by:**



---

**Source URL:** <https://globalprojects.ucsf.edu/project/single-arm-open-label-phase-2-study-mgah22-fc-optimized-chimeric-anti-her2-monoclonal>